Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)

China flag China · Delayed Price · Currency is CNY
33.64
-0.39 (-1.15%)
May 8, 2026, 3:04 PM CST
Market Cap53.50B -1.4%
Revenue (ttm)18.38B -8.0%
Net Income1.57B -37.0%
EPS0.99 -36.9%
Shares Out1.59B
PE Ratio33.97
Forward PE21.68
Dividend0.59 (1.75%)
Ex-Dividend DateMay 11, 2026
Volume9,327,655
Average Volume18,713,551
Open34.01
Previous Close34.03
Day's Range33.44 - 34.16
52-Week Range28.14 - 41.72
Beta-0.12
RSI48.29
Earnings DateAug 18, 2026

About SHE:002422

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumo... [Read more]

Sector Healthcare
Founded 1996
Employees 20,127
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002422
Full Company Profile

Financial Performance

In 2025, SHE:002422's revenue was 18.51 billion, a decrease of -15.13% compared to the previous year's 21.81 billion. Earnings were 1.70 billion, a decrease of -42.03%.

Financial Statements

News

Sichuan Kelun Pharmaceutical Earnings Call Transcript: H2 2025

Revenue grew 6.5% to RMB 2.06 billion in 2025, driven by expanded commercialization and strong R&D pipeline. Gross margin outpaced revenue growth, but net loss increased due to higher sales and R&D expenses. Multiple new approvals, global partnerships, and AI-driven R&D position the company for further growth.

6 weeks ago - Transcripts

Sichuan Kelun Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

The company highlighted its leadership in ADC innovation, with four approved products and a robust pipeline targeting oncology and beyond. Strategic partnerships and inclusion in China's NRDL 2025 support commercialization and global expansion.

4 months ago - Transcripts

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

5 months ago - Nasdaq

Sichuan Kelun Pharmaceutical Earnings Call Transcript: H1 2025

Reported RMB 950 million revenue in 1H 2025, driven by first-year commercialization and robust R&D partnerships. Lung cancer led sales, with strong clinical progress and a solid cash position supporting future growth.

9 months ago - Transcripts